The Levitronix CentriMag ventricular assist device as a bridge to decision in patients with end-stage heart failure: Our single-center experience

dc.authorid Rabus, Murat Bulent/0000-0002-4952-8637
dc.authorid salihi, salih/0000-0002-4477-9605
dc.authorscopusid 6601979334
dc.authorscopusid 56380523500
dc.authorscopusid 57196454344
dc.authorscopusid 23667169700
dc.authorscopusid 35290488300
dc.authorscopusid 6602499167
dc.authorwosid salihi, salih/AAF-1994-2019
dc.authorwosid Cevirme, Deniz/V-9568-2017
dc.authorwosid Rabus, Murat Bulent/HKV-8537-2023
dc.authorwosid salihi, salih/JGL-9646-2023
dc.contributor.author Rabus, Murat Bulent
dc.contributor.author Salihi, Salih
dc.contributor.author Hasanov, Sarkhan
dc.contributor.author Fedakar, Ali
dc.contributor.author Cevirme, Deniz
dc.contributor.author Balkanay, Mehmet
dc.date.accessioned 2024-05-25T11:20:21Z
dc.date.available 2024-05-25T11:20:21Z
dc.date.issued 2017
dc.department Okan University en_US
dc.department-temp [Rabus, Murat Bulent; Fedakar, Ali; Cevirme, Deniz] Univ Hlth Sci, Kartal Kosuyolu Yuksek Ihtisas Training & Res Hos, Dept Cardiovasc Surg, Istanbul, Turkey; [Salihi, Salih] Okan Univ, Fac Med, Dept Cardiovasc Surg, Istanbul, Turkey; [Hasanov, Sarkhan] Kolan Hosp, Dept Cardiovasc Surg, Istanbul, Turkey; [Balkanay, Mehmet] Izmir Katip Celebi Univ, Fac Med, Dept Cardiovasc Surg, Izmir, Turkey en_US
dc.description Rabus, Murat Bulent/0000-0002-4952-8637; salihi, salih/0000-0002-4477-9605 en_US
dc.description.abstract Background: In this study, we report early outcomes of Levitronix CentriMag device implantation for bridge to decision for patients with end-stage heart failure in a single center. Methods: We retrospectively analyzed data of a total of 41 patients (30 males, 11 females: mean age 30.2 +/- 15 years; range 7 to 59 years) with end-stage heart failure who received a Levitronix CentriMag support for bridge to decision between December 2010 and September 2014. Devices were implanted in the left (n=38), right (n=1), or biventricular (n=2) configuration. Support was continued until recovery, transplantation or implantation of a long-term ventricular assist device. Results: The mean preoperative left ventricular ejection fraction was 17 +/- 2.3%. The mean support time was 38 (range 1 to 192) days. Sixteen patients (39%) survived and moved on to the next phase of the treatment. Of these patients, 11 (27%) underwent cardiac transplantation operations and five (12%) received long-term ventricular assist devices. After the CentriMag implantation, 30-day survival rate was 49% in 20 patients. Bleeding requiring re-operation was observed in 13 patients (32%). Two patients (4.8%) had sternal wound infections. Device dysfunction was observed in one patient (2.4%). Non-survivors had a higher rate of sepsis and renal failure, compared to the survivors (p<0.05). Conclusion: The CentriMag system provides an effective temporary mechanical circulatory support for cardiac failure. The ease of implantation and high rate of successful device weaning encourage the use of CentriMag system as a temporary ventricle support. en_US
dc.identifier.citationcount 2
dc.identifier.doi 10.5606/tgkdc.dergisi.2017.13843
dc.identifier.endpage 549 en_US
dc.identifier.issn 1301-5680
dc.identifier.issue 4 en_US
dc.identifier.scopus 2-s2.0-85033362401
dc.identifier.scopusquality Q4
dc.identifier.startpage 543 en_US
dc.identifier.uri https://doi.org/10.5606/tgkdc.dergisi.2017.13843
dc.identifier.uri https://hdl.handle.net/20.500.14517/477
dc.identifier.volume 25 en_US
dc.identifier.wos WOS:000418417300005
dc.identifier.wosquality Q4
dc.language.iso en
dc.publisher Baycinar Medical Publ-baycinar Tibbi Yayincilik en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.scopus.citedbyCount 3
dc.subject Cardiogenic shock en_US
dc.subject end-stage heart failure en_US
dc.subject ventricular assist device en_US
dc.title The Levitronix CentriMag ventricular assist device as a bridge to decision in patients with end-stage heart failure: Our single-center experience en_US
dc.type Article en_US
dc.wos.citedbyCount 2

Files